Incyte INCY
NASDAQ INCY
$128.03 -0.80 (-0.62%)
As of: Sep 3, 2026 · 3:59 PM EDT

Incyte (INCY) Gains from Investment Securities (2016 - 2026)

Incyte's (INCY) quarterly Gains from Investment Securities came in at $2.5 million in Q2 2026, down 89.02% YoY from $22.8 million in Q2 2025, and up 1587.5% on a QoQ basis from -$168000.0 in Q1 2026.

Analysis

Incyte (INCY) Gains from Investment Securities (2016 - 2026) Analysis & Trends

Incyte (INCY) has 11 years of Gains from Investment Securities data on file, last reported at $2.5 million in Q2 2026.

  • Quarterly Gains from Investment Securities fell 89.02% year-over-year to $2.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$38.1 million (down 171.01% YoY) and the FY2025 annual result came in at -$6.1 million, down 130.95% from the prior year.
  • Gains from Investment Securities improved to $2.5 million in Q2 2026, from -$168000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $24.3 million in Q4 2022 to a low of -$28.3 million in Q4 2025.
  • A 5-year average of $3.2 million and a median of $2.9 million in 2022 frame the typical range for Gains from Investment Securities.
  • Annual changes were most pronounced in 2022 — Gains from Investment Securities tumbled 852.34% — and 2024, when it soared 5595.31%.
  • Tracing INCY's Gains from Investment Securities over 5 years: stood at $24.3 million in 2022, then tumbled by 38.15% to $15.1 million in 2023, then plunged by 126.86% to -$4.0 million in 2024, then tumbled by 598.76% to -$28.3 million in 2025, then surged by 108.84% to $2.5 million in 2026.
  • The last three Gains from Investment Securities figures came in at $2.5 million (Q2 2026), -$168000.0 (Q1 2026), and -$28.3 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 141.52 Bn 133.66 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 86.69 Bn 78.69 Bn 3.93 Bn
3 Argenx Se 64.63 Bn 59.45 Bn 1.37 Bn
4 Moderna 59.30 Bn 54.16 Bn 52.00 Mn
5 Revolution Medicines 44.41 Bn 44.41 Bn -
6 BeOne Medicines 40.45 Bn 35.35 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.29 Bn 31.98 Bn 992.69 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn -
9 Insmed 27.55 Bn 26.39 Bn 358.27 Mn
10 Incyte 25.65 Bn 21.11 Bn 1.57 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.50 Mn
Mar 31, 2026 -168,000.00
Dec 31, 2025 -28.26 Mn
Sep 30, 2025 -12.20 Mn
Jun 30, 2025 22.76 Mn
Mar 31, 2025 11.57 Mn
Dec 31, 2024 -4.04 Mn
Sep 30, 2024 23.41 Mn
Jun 30, 2024 893,000.00
Mar 31, 2024 -456,000.00
Dec 31, 2023 15.06 Mn
Sep 30, 2023 -426,000.00
Jun 30, 2023 8.37 Mn
Mar 31, 2023 6.20 Mn
Dec 31, 2022 24.35 Mn
Sep 30, 2022 -21.89 Mn
Jun 30, 2022 3.31 Mn
Mar 31, 2022 6.38 Mn
Dec 31, 2021 1.67 Mn
Sep 30, 2021 2.91 Mn